Healx
Healx is a Cambridge-based rare disease biotech using its proprietary Healnet AI platform for drug repurposing and discovery. It serves pharmaceutical companies through licensing deals and patient advocacy groups via its Rare Treatment Accelerator, with clinical-stage assets in neurofibromatosis and oncology.
- Company typePrivate
- Founded2014
- HeadquartersCambridge, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Healx does
Healx is a Cambridge, UK-based rare disease biotechnology company founded in 2014 that applies generative AI and knowledge-graph-based drug discovery to identify repurposed and combination therapies for indications lacking approved treatments. The company's core technology is the Healnet platform, which integrates 100M+ high-confidence drug-disease relationships and 1B+ extracted entities drawn from biomedical literature and multi-omics datasets, enabling parallel prioritization of candidate molecules for rare disease programs. Healx operates a portfolio of clinical and preclinical assets: HLX-1502 (Phase 2, Neurofibromatosis Type 1, FDA Fast Track designated), HLX-4310 (IND cleared, osteosarcoma), HLX-0206 (Fragile X Syndrome), HLX-0553 (Angelman Syndrome), plus undisclosed early-stage programs in NF1, oncology, and spinal cord injury.
The company's go-to-market is structured around enterprise partnerships rather than product sales. Healx monetizes through co-development and licensing arrangements with pharmaceutical companies (Sanofi, Boehringer Ingelheim, Ono Pharmaceutical, GW Pharma), milestone-based agreements, and the Rare Treatment Accelerator program that supplies AI-enabled drug discovery and clinical expertise to patient advocacy groups, academics, and early-stage biotechs (often at no cost to the partner). Patient advocacy organizations — including FRAXA, Children's Tumor Foundation, FAST, PKD Charity, and Muscular Dystrophy UK — serve a dual role as scientific collaborators and community-engagement channels. The company has raised over $100M cumulatively across funding rounds led by Atomico, Balderton Capital, and Amadeus Capital Partners, with strategic backing from AstraZeneca and Intel Capital. Headcount stands at 51-100 employees, with leadership combining AI/ML expertise and senior pharma R&D pedigree (co-founder David Brown co-invented Viagra at Pfizer).
Healx firmographics
Firmographics- Name
- Healx
- Legal name
- Healx Ltd.
- Website
- https://healx.ai
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Healx is a Cambridge-based rare disease biotech using its proprietary Healnet AI platform for drug repurposing and discovery. It serves pharmaceutical companies through licensing deals and patient advocacy groups via its Rare Treatment Accelerator, with clinical-stage assets in neurofibromatosis and oncology.
- Ownership category
- akta.pro rank
Healx industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Condition-specific Digital Therapeutics (DTx) (HLACANAA)
- akta.pro secondary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where Healx is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Healx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Co-development and Licensing Deals: Healx partners with pharmaceutical companies, biotech firms, and patient groups to co-develop or license treatments. Partnerships include co-development arrangements where Healx provides AI drug discovery services in exchange for development milestones and royalties.
- Rare Treatment Accelerator Program: Healx provides financial resources, drug discovery and clinical expertise to selected participants to progress drug redevelopment projects toward clinical trials, typically at no cost to partners, with potential co-funding arrangements for continuing pre-clinical work.
- Strategic Partnerships with Pharma: Partnerships with pharmaceutical companies like Sanofi and Boehringer Ingelheim for AI-driven drug discovery targeting specific disease areas, with potential milestone payments and royalties.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Healx product offering
Product offeringCore offering
Healx is an AI-powered rare disease biotechnology company that operates the Healnet platform, leveraging generative AI, knowledge graphs, NLP, and machine learning to identify novel drug-disease relationships and accelerate drug repurposing and combination therapy development for rare diseases. The company develops its own therapeutic pipeline (HLX-1502, HLX-4310, HLX-0206, HLX-0553) and offers co-development, licensing, and partnership arrangements to pharmaceutical companies, biotech firms, academic institutions, and patient advocacy groups.
Product overview
Healx is an AI-powered biotech company that has developed a unified technology platform (Healnet) for drug discovery focused on rare diseases. The platform leverages generative AI, knowledge graphs, and machine learning to identify novel drug-disease relationships and accelerate treatment development. The company's product portfolio consists of therapeutic candidates at various clinical stages: HLX-1502 (Phase 2, Neurofibromatosis Type 1), HLX-4310 (IND cleared, Osteosarcoma), HLX-0206 (Fragile X Syndrome), and HLX-0553 (Angelman Syndrome). Additionally, Healx offers the Rare Treatment Accelerator program to partner with external researchers for drug redevelopment projects.
Differentiator
Problem solved
Functional benefit
Products and services
- Healnet AI Platform
Quantifiable outcome
- Delivered decades-worth of drug discovery in less than two years for Fragile X Syndrome partnership with FRAXA
- +2 more outcomes
Companies that use Healx
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles4 records
Healx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature5 records
Healx partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- Vuja De SciencescoreStrategic transaction combining Healx's AI platform with Vuja De's clinical-stage osteosarcoma program. FDA has cleared IND for HLX-4310. Partnership reinforces Healx's focus on rare and pediatric oncology, with Dr. David Warshawsky joining Healx as Global Head of Metastatic Prevention.
- SCI VenturescorePartnership to utilize AI-driven platforms to discover therapies for spinal cord injury (SCI). The partnership combines Healx's machine learning and drug discovery expertise with SCI Ventures' scientific insight and datasets, targeting a condition affecting over 20 million people worldwide. Backing includes Christopher & Dana Reeve Foundation, Wings for Life, Spinal Research.
- SanoficoreAI collaboration focused on targeting novel rare disease indications. Partnership aims to leverage artificial intelligence to accelerate the development of new treatments for rare diseases using Healx's AI drug discovery platform.
- PKD CharitycoreCollaboration to apply AI to the discovery of novel treatments for rare kidney diseases including polycystic kidney disease (PKD).
- FAST (Foundation for Angelman Syndrome Therapeutics)corePartnership to accelerate novel treatments for Angelman Syndrome towards the clinic using Healx's AI platform and FAST's scientific expertise.
- FRAXA Research FoundationcoreDrug discovery partnership for Fragile X Syndrome. Partnership delivered decades-worth of drug discovery in less than two years, advancing multiple clinical candidates.
- Children's Tumor FoundationcorePartnership to progress Neurofibromatosis treatments. Foundation also providing investment to advance NF1 treatments. Simone Manso from Healx serves on CTF Board.
- Muscular Dystrophy UKminorCollaboration to find new treatments for rare muscle-wasting diseases.
- Mission: CureminorPartnership to discover and advance treatments for chronic pancreatitis, potentially the first treatments for this condition.
- Ataxia UK and FARAminorPartnership to find treatments for Friedreich's Ataxia, a rare neurodegenerative condition.
- Boehringer IngelheimcoreAI-based drug discovery partnership for rare neurological diseases. Healx leverages its AI platform to identify new treatment approaches.
- Ono PharmaceuticalminorAI-powered indication expansion partnership to find new uses for existing compounds.
- Boston Children's HospitalminorCollaboration for Barth Syndrome drug discovery research.
- Institute of Cancer Research (ICR)minorPartnership to develop potential new AI-derived treatments for DIPG, a rare childhood brain tumor.
- National Pediatric Cancer FoundationcoreCollaboration through the Sunshine Project for Phase 1/2 clinical trial of HLX-4310 in adolescent and adult patients with relapsed or refractory sarcoma, including osteosarcoma.
Scale indicators5 records
Recent moves6 records
Expansion highlights7 records
Healx competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning. Most direct comparable as a platform-based AI biotech pursuing multiple therapeutic programs with pharma partnerships.
- Exscientia: AI-driven pharma company using generative AI and active learning to design novel drug candidates. Closest comparable in business model of partnering with large pharma (Sanofi, BMS) and operating an end-to-end AI drug discovery platform.
- Insitro: AI-driven drug discovery company combining ML with high-throughput biology for predictive modeling of disease and therapeutics. Comparable in using AI for indication discovery and partnering with pharma (Bristol-Myers Squibb, Eli Lilly).
- BenevolentAI: UK-based AI drug discovery company using knowledge graphs and ML for target identification. Direct comparable in geography, technology approach (knowledge graphs), and pharma partnership model (AstraZeneca).
- Schrödinger: Computational drug discovery platform combining physics-based simulation with ML. Comparable in applying computational methods to drug discovery, with both internal pipeline and pharma software partnerships (Bristol-Myers Squibb, Bayer).
- Atomwise: AI drug discovery company using structure-based deep learning for hit identification. Comparable as a private AI biotech pursuing pharma partnerships across multiple therapeutic areas.
- Insilico Medicine: AI-driven biotech using generative AI for de novo drug design with clinical-stage assets. Comparable in applying generative AI end-to-end from target discovery to clinical development with pharma partnerships.
Broad incumbents
- Ultragenyx Pharmaceutical: Established commercial rare disease biotech with multiple approved and clinical-stage products. Comparable in therapeutic area focus (rare diseases) and partnership-based development approach, though significantly larger and more mature.
- BioMarin Pharmaceutical: Large rare disease-focused biotech with multiple approved enzyme replacement and gene therapies. Comparable in deep rare disease focus and regulatory expertise, though at much greater commercial scale than Healx.
- Alexion (AstraZeneca Rare Disease): Major rare disease division of AstraZeneca with multiple approved rare disease therapies. Comparable as a large strategic partner (Healx's investor and partner candidate) and benchmark for what successful rare disease commercialization looks like at scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Healx social profiles
Digital presenceHealx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Healx leadership team
Management profileNumber of profiles
Profiles18 records
Healx funding detail
Funding detailFunding overview
Funding rounds7 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Healx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Healx
What does Healx do?
Healx is an AI-powered rare disease biotechnology company that operates the Healnet platform, leveraging generative AI, knowledge graphs, NLP, and machine learning to identify novel drug-disease relationships and accelerate drug repurposing and combination therapy development for rare diseases. The company develops its own therapeutic pipeline (HLX-1502, HLX-4310, HLX-0206, HLX-0553) and offers co-development, licensing, and partnership arrangements to pharmaceutical companies, biotech firms, academic institutions, and patient advocacy groups.
Is Healx a public or private company?
Healx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Healx founded?
Healx was founded in 2014. It employs 51 to 100 people.
Where is Healx based?
Healx is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Healx make money?
Three revenue lines are on record. Co-development and Licensing Deals are the primary driver. The others are rare Treatment Accelerator Program and strategic Partnerships with Pharma.
Who are Healx's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Exscientia, Insitro, BenevolentAI, Schrödinger, Atomwise and Insilico Medicine. Broad incumbents are Ultragenyx Pharmaceutical, BioMarin Pharmaceutical and Alexion (AstraZeneca Rare Disease).
Does Healx have an API?
No public API is recorded for Healx.
What industry is Healx in?
Healx's product category is AI Drug Discovery. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 541714 and its SIC code is 2834.